유전성 평활근종증 신세포암 - 신장암의 유전적 원인과 소인에 관한 연구
유전성 평활근종증 신세포암(HLRCC): 질환 유전자 규명 및 신장암 소인 특성 규명
This study will investigate what causes hereditary leiomyomatosis renal (kidney) cell cancer, or HLRCC, and how the disease is related to the development of kidney tumors. Leiomyomas are benign (non-cancerous) tumors arising from smooth muscle. HLRCC can cause various health problems. Some people develop red bumps on their skin that can be painful at times. Some women with HLRCC can develop leiomyomas of the uterus. In some families, people with HLRCC develop kidney tumors. This study will try to determine:
- What gene changes (mutations) cause HLRCC
- What kind of kidney tumors develop in HLRCC and how they grow
- What the chance is that a person with HLRCC will develop a kidney tumor
People with known or suspected HLRCC (and their family members of any age) may be eligible for this study. This includes people in families in which one or more members has skin leiomyoma and kidney cancer; skin leiomyoma and uterine leiomyoma; multiple skin leiomyomas; kidney cancer and uterine leiomyomas, or kidney cancer consistent with HLRCC, including, but not limited to, collecting duct or papillary, type II. Candidates will be screened with a physical examination, family history, and, for affected family members, a review of medical records, including pathology slides and computed tomography (CT) or magnetic resonance imaging (MRI) scans.
Participants will undergo tests and procedures that may include the following:
-
Review of medical records, x-rays, and tissue slides
-
Physical examination and family history
-
Skin examination
-
Gynecological examination for women
-
Interviews with a cancer doctor, cancer nurses, kidney surgeon, and genetic counselor
-
Blood tests for:
- Genetic research to identify the gene responsible for HLRCC
- Evaluation of liver, kidney, heart, pancreas, and thyroid function
- Complete blood count and clotting profile
- Pregnancy test for pre-menopausal women
- PSA test for prostate cancer in men over age 40
-
CT or MRI scans (for participants 15 years of age and older only)
-
Skin biopsy (surgical removal of a small sample of skin tissue)
-
Cheek swab or mouth rinse to collect cells for genetic analysis
-
Medical photographs of lesions
-
Questionnaire
When the tests are completed, participants will discuss the results with a doctor and possibly a genetic nurse or genetic counselor. The genetic findings will not be revealed to participants because their meaning and implications may not yet be understood. Participants may be asked to return to NIH from every 3 months to every 3 years, depending on their condition, for follow-up examinations and tests.
연구 개요
상태
상태
상세 설명
Background:
- Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a rare autosomal dominantly inherited disorder which confers susceptibility to develop cutaneous and uterine leiomyomas and renal cell carcinoma.
- HLRCC is caused by mutations in the Krebs cycle enzyme, fumarate hydratase localized on chromosome 1q42.3-q43.
Objectives:
- Define the risk of developing renal cancer, cutaneous leiomyoma and uterine leiomyoma in this hereditary cancer syndrome
- Define the types and characteristics (including patterns of growth) of renal cancer associated with HLRCC
- Determine the incidence and characteristics of HLRCC-associated fumarate hydratase gene mutations
- Determine genotype/phenotype correlations
- Determine if other genes cause HLRCC
Eligibility:
-
Individuals that meet one or more of the following criteria:
-
Suspected or known to have phenotype or genotype suggestive of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC), such as:
- Cutaneous leiomyoma and kidney cancer
- Cutaneous leiomyoma and uterine leiomyoma
- Multiple cutaneous leiomyoma
- Kidney cancer and uterine leiomyomata
or
-Renal tumor histology consistent with HLRCC including, but not limited to: Collecting Duct and/or Papillary, Type II
or
-Are a relative (related by blood) of an individual with a confirmed or suspected diagnosis of HLRCC
Design:
- These rare biological families will be recruited to genetically confirm diagnosis, determine size and location of renal tumors, size at presentation, growth rate and metastatic potential of renal tumors.
- Genetic testing will be offered to gain appreciation of the effect of mutations on the relative activity of various germline and somatic mutations.
- We will determine if there is a relationship between mutation and disease phenotype.
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Deborah A Nielsen, R.N.
- 전화번호: (240) 760-6247
- 이메일: deborah.nielsen@nih.gov
연구 연락처 백업
- 이름: W. Marston Linehan, M.D.
- 전화번호: (240) 858-3700
- 이메일: linehanm@mail.nih.gov
연구 장소
-
-
Maryland
-
Bethesda, Maryland, 미국, 20892
- 모병
- National Institutes of Health Clinical Center
-
연락하다:
- For more information at the NIH Clinical Center contact National Cancer Institute Referral Office
- 전화번호: 888-624-1937
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
An individual (including patient) from a family in which one or more family member have: cutaneous leiomyoma and kidney cancer, cutaneous leiomyoma and uterine leiomyoma, multiple cutaneous leiomyoma, kidney cancer and uterine leiomyomata, renal tumor histology consistent with HLRCC including, but not limited to: Collecting Duct and/or Papillary, Type II.
설명
-
INCLUSION CRITERIA:
-
Individuals that meet one or more of the following criteria:
-
Suspected or known to have phenotype or genotype suggestive of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC), such as:
- Cutaneous leiomyoma and kidney cancer; or
- Cutaneous leiomyoma and uterine leiomyoma; or
- Multiple cutaneous leiomyoma; or
- Kidney cancer and uterine leiomyomata
-
OR
--Renal tumor histology consistent with HLRCC including, but not limited to: Collecting Duct and/or Papillary, Type II
OR
--Are a relative (related by blood) of an individual with a confirmed or suspected diagnosis of HLRCC.
- Participants must be >= 2 years of age.
- All participants and parents/guardians, for children younger than 18 years of age, must sign an informed consent document indicating their understanding of the investigational nature and the risks of this study before any protocol related studies are performed.
EXCLUSION CRITERIA:
None
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: CASE_ONLY
- 시간 관점: PROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
|---|
|
1 / Individuals
Individuals with known or suspected Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC) |
|
2 / Family Members
Family members (related by blood) of individuals who have or are suspected of having Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC) |
|
3 / Non-Biologic Family Members
Spouses enrolled primarily for linkage analysis (Spouses have been removed from the inclusion criteria for this study. This closed cohort is for spouses previously enrolled on study.) |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Determine the incidence and characteristics of HLRCC-associated fumarate hydratase gene mutations.
기간: on-going
|
Molecular genetic differences between normal and tumorigenic fumarate hydratase (fumerase) mutations. |
on-going
|
|
Determine the clinical manifestations of HLRCC
기간: on-going
|
Collection of blood, urine and/or benign and malignant tissue. |
on-going
|
|
Determine if other genes cause HLRCC.
기간: on-going
|
Molecular genetic differences between normal and tumorigenic cells. |
on-going
|
|
Determine genotype/phenotype correlations.
기간: on-going
|
Detection and expression analysis of gene(s). |
on-going
|
|
Define the types and characteristics (including patterns of growth) of renal cancer associated with HLRCC.
기간: on-going
|
Detection and expression analysis of gene(s). |
on-going
|
|
Define the risk of developing renal cancer, cutaneous leiomyoma and uterine leiomyoma in this hereditary cancer syndrome.
기간: on-going
|
Collection of blood, urine and/or benign and malignant tissue. |
on-going
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: W. Marston Linehan, M.D., National Cancer Institute (NCI)
간행물 및 유용한 링크
일반 간행물
- Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA. 1995 Feb 15;273(7):564-70. No abstract available.
- Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993 May 28;260(5112):1317-20. doi: 10.1126/science.8493574.
- Zbar B, Tory K, Merino M, Schmidt L, Glenn G, Choyke P, Walther MM, Lerman M, Linehan WM. Hereditary papillary renal cell carcinoma. J Urol. 1994 Mar;151(3):561-6. doi: 10.1016/s0022-5347(17)35015-2.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정된)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 030066
- 03-C-0066
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
All IPD recorded in the medical record will be shared with intramural investigators upon request. @@@@@@In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.
IPD 공유 기간
Clinical data available during the study and indefinitely.@@@@@@Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.
IPD 공유 액세스 기준
Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.@@@@@@Genomic data are made available via dbGaP through requests to the data custodians.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .